Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01373086 · ClinicalTrials.gov registry record · Phase 2
LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01373086 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 19 participants.
The verdict
NCT01373086, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.
Interventions
- DRUG Placebo
- DRUG Eplerenone
- DRUG LFF269
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01373086
The ClinicalTrials.gov registry entry for NCT01373086 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01373086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01373086 about?
NCT01373086 is a clinical study titled "LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension". This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.
What is the current status of trial NCT01373086?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2011-05. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01373086?
The interventions under investigation include: Placebo (DRUG), Eplerenone (DRUG), LFF269 (DRUG).
Who is sponsoring clinical trial NCT01373086?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.